Skip to main content
    E

    Enanta Pharmaceuticals Inc (ENTA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $10.67
    -0.32 (-2.91%)

    Market Cap: $320.09M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Enanta Pharmaceuticals Inc (ENTA) Earnings: Report Dates and Results

    Updated Aug 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Enanta Pharmaceuticals (ENTA) is expected to report earnings on Feb 8, 2027. In the quarter ended Jun 30, 2026, Enanta Pharmaceuticals reported EPS of -$0.67, below the -$0.37 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    64%(25/39)
    Avg Surprise
    +21.59%

    Upcoming Estimates

    Reports Feb 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.41
    Range-$0.48 - -$0.33
    2 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.37-11.0%
    60d ago-$0.37-11.0%
    30d ago-$0.37-11.0%
    7d ago-$0.37-11.0%
    Current-$0.41
    Revenue Consensus
    $16.25M
    Range$14.50M - $18.00M
    2 analysts

    Next Report

    ENTA has an expected report date of Feb 8, 2027.

    ENTA Earnings Call

    The latest ENTA earnings call transcript on file is labeled 2024Q2.

    Read the 2024Q2 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, ENTA beat 26 and missed 14. Revenue for the quarter ended Jun 30, 2026 was $14.36M, down 21.6% from $18.31M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Jun 30, 2026-$0.67-$0.37-$0.77 - -$0.22-81.08%MissN/A52 up, 0 downAug 10, 2026$14.36M
    Mar 31, 2026-$0.45-$0.57N/A+21.05%BeatN/A52 up, 0 downMay 11, 2026$17.16M
    Dec 31, 2025-$0.42-$0.88-$1.23 - -$0.53+52.27%BeatN/A51 up, 1 downFeb 9, 2026$18.61M
    Sep 30, 2025-$0.87-$1.01-$1.19 - -$0.88+13.86%BeatN/A5N/ANov 17, 2025$15.13M
    Jun 30, 2025-$0.85-$0.88-$1.68 - $0.55+3.41%BeatN/A40 up, 2 downAug 11, 2025$18.31M
    Mar 31, 2025-$1.06-$1.14-$1.42 - -$0.98+7.02%BeatN/A52 up, 0 downMay 12, 2025$14.93M
    Dec 31, 2024-$1.05-$1.35-$1.50 - -$1.16+22.22%BeatN/A40 up, 3 downFeb 10, 2025$16.96M
    Sep 30, 2024-$1.36-$0.92-$1.50 - -$0.07-47.83%MissN/A53 up, 1 downNov 25, 2024$14.61M
    Jun 30, 2024-$1.07-$1.41-$1.73 - -$1.18+24.11%BeatN/A70 up, 0 downAug 5, 2024$17.97M
    Mar 31, 2024-$1.47-$1.40-$1.63 - -$1.11-5.00%MissN/A70 up, 0 downMay 6, 2024$17.05M
    Dec 31, 2023-$1.58-$1.23-$1.70 - -$0.90-28.46%MissN/A50 up, 0 downFeb 7, 2024$18.00M
    Sep 30, 2023-$1.33-$2.21-$2.35 - -$1.68+39.82%BeatN/A60 up, 0 downNov 20, 2023$18.93M
    Jun 30, 2023-$1.86-$2.19-$2.97 - -$1.86+15.07%BeatN/A60 up, 0 downAug 7, 2023$18.89M
    Mar 31, 2023-$1.79-$1.93-$2.30 - -$1.39+7.25%BeatN/A80 up, 0 downMay 8, 2023$17.80M
    Dec 31, 2022-$1.39-$1.60-$1.81 - -$1.37+13.13%BeatN/A62 up, 0 downFeb 7, 2023$23.59M
    Sep 30, 2022-$1.27-$1.35-$1.61 - -$1.10+5.93%BeatN/A70 up, 0 downNov 21, 2022$20.32M
    Jun 30, 2022-$1.53-$1.39-$1.71 - -$0.83-10.07%MissN/A81 up, 1 downAug 8, 2022$19.48M
    Mar 31, 2022-$1.63-$1.41-$1.82 - -$1.19-15.60%MissN/A90 up, 0 downMay 9, 2022$18.72M
    Dec 31, 2021-$1.48-$1.11-$1.43 - -$0.77-33.33%MissN/A8N/AFeb 8, 2022$27.65M
    Sep 30, 2021-$1.22-$1.19-$1.59 - -$0.60-2.52%MissN/A9N/ANov 22, 2021$23.57M
    Jun 30, 2021-$1.19-$1.29-$1.47 - -$1.02+7.75%BeatN/A8N/AAug 5, 2021$21.62M
    Mar 31, 2021-$1.09-$0.97-$1.13 - -$0.51-12.37%MissN/A8N/AMay 6, 2021$20.13M
    Dec 31, 2020-$0.41-$0.77-$1.02 - -$0.58+46.75%Beat-163.1%7N/AFeb 8, 2021$31.74M
    Sep 30, 2020-$1.46-$0.97-$1.29 - -$0.71-50.52%Miss-431.8%7N/ANov 23, 2020$23.63M
    Jun 30, 2020-$0.71-$0.96-$1.25 - -$0.26+26.04%Beat-315.2%6N/AAug 4, 2020$18.65M
    Mar 31, 2020-$0.30-$0.72-$1.80 - -$0.45+58.33%Beat-250.0%7N/AMay 6, 2020$27.62M
    Dec 31, 2019$0.65$0.60$0.38 - $0.76+8.33%Beat-48.0%6N/AFeb 6, 2020$52.57M
    Sep 30, 2019$0.44$0.56$0.34 - $1.10-21.43%Miss-66.2%7N/ANov 21, 2019$51.31M
    Jun 30, 2019$0.33$0.17$0.01 - $0.51+94.12%Beat-66.0%7N/AAug 6, 2019$44.37M
    Mar 31, 2019$0.20-$0.05-$0.30 - $0.20+500.00%Beat-67.2%7N/AMay 7, 2019$39.63M
    Dec 31, 2018$1.25$1.29$1.10 - $1.72-3.10%Miss+212.5%7N/AFeb 6, 2019$69.89M
    Sep 30, 2018$1.30$1.19$1.05 - $1.33+9.24%Beat-30.1%6N/ANov 26, 2018$67.20M
    Jun 30, 2018$0.97$0.90$0.68 - $1.18+7.78%BeatN/A6N/AAug 7, 2018$57.26M
    Mar 31, 2018$0.61$0.25$0.12 - $0.87+144.00%BeatN/A4N/AMay 8, 2018$44.05M
    Dec 31, 2017$0.40$0.27-$0.04 - $0.36+48.15%BeatN/A4N/AFeb 7, 2018$38.11M
    Sep 30, 2017$1.86$2.13$1.81 - $2.83-12.68%MissN/A4N/ANov 20, 2017$75.93M
    Jun 30, 2017-$0.44-$0.48-$0.59 - -$0.39+8.33%BeatN/A3N/AAug 7, 2017$7.51M
    Mar 31, 2017-$0.28-$0.38N/A+26.32%BeatN/AN/AN/AMay 8, 2017$8.96M
    Dec 31, 2016-$0.26-$0.18N/A-44.44%Miss-119.1%N/AN/AFeb 8, 2017$10.42M
    Sep 30, 2016-$0.09-$0.18N/A+50.00%Beat-131.0%N/AN/ANov 21, 2016$12.84M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Sep 30, 2026 was -$1.54, after -$3.83 the year before. It was $0.88 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Sep 30, 2026-$1.54N/A
    Sep 30, 2025-$3.83N/A
    Sep 30, 2024-$5.48N/A
    Sep 30, 2023-$6.37N/A
    Sep 30, 2022-$5.91N/A
    Sep 30, 2021-$3.91N/A
    Sep 30, 2020-$1.82-182.0%
    Sep 30, 2019$2.22-32.3%
    Sep 30, 2018$3.28+272.7%
    Sep 30, 2017$0.88N/A

    Earnings Calls

    The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 5,200 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2024Q2Jun 30, 20245,21812

    2024Q2 Earnings Call

    Opening remarks

    Jennifer Viera Investor Relations Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter financial results was issued this afternoon and is available on our website. Making remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Chief Product Strategy Officer, will be available during the Q&A portion of the call. Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements. These statements may include our plans and expectations with respect to our research and development pipeline and financial projections. All of these statements involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from the statements. A description of these risks is in our most recent Form 10-K and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call. I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?

    Jay Luly President and CEO Thank you, Jennifer, and good afternoon, everyone. Throughout 2024, Enanta has remained squarely focused on advancing our virology and immunology pipeline to bring important oral therapeutics to market. Our commitment to developing treatments for areas of high unmet need is driven by our mission to transform patients' lives with curative therapies. And we are determined to achieve our milestones to drive near- and long-term shareholder value to fulfill this mission. Our focus is critical as we approach meaningful inflection points with the potential to develop the first antiviral treatment for RSV. With that, today, I'll begin with an overview of our programs, beginning with our respiratory syncytial virus or RSV programs and then discuss our immunology program for chronic spontaneous urticaria or CSU. As a reminder, RSV is a severe respiratory infection associated with significant morbidity and mortality that can cause serious disease in infants, children, and other high-risk populations, including the elderly and individuals with congestive heart failure, chronic obstructive pulmonary disease, asthma, or other high-risk conditions. Despite the availability of prophylactic options such as vaccines and monoclonal antibodies, there's a clear need for a safe and effective oral RSV antiviral treatment. Adoption of vaccines has been suboptimal, and breakthrough infections still occur. Additionally, pediatric monoclonal antibodies only provide passive immunity for a few months and not long-term protection against the infection. With this clear need, we have developed a broad clinical program that has the potential to enable multiple opportunities to treat RSV.

    Frequently Asked Questions About ENTA

    When is Enanta Pharmaceuticals's next earnings date?

    Enanta Pharmaceuticals's next earnings report is expected for Feb 8, 2027.

    Did ENTA beat earnings estimates last quarter?

    No. Enanta Pharmaceuticals reported EPS of -$0.67 for the quarter ended Jun 30, 2026, below the -$0.37 estimate by 81.08%.

    What EPS do analysts expect from ENTA next quarter?

    The consensus EPS estimate for Enanta Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.41 from 2 analysts, with estimates from -$0.48 to -$0.33.

    How often does ENTA beat earnings estimates?

    Enanta Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -1.13%.